SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
New Zealand Fast-Tracks Gold Mining as Industry Revival Gains Momentum 
Oil Prices Drop as Middle East Supply Recovery Eases Market Concerns 
Japan Manufacturing Growth Accelerates in June as Orders Surge Despite Iran War Cost Pressures 
U.S.-Iran Diplomacy Helps Drive Gasoline Prices Down 15% From May Highs 
Gold Falls Below $4,000 as Strong Dollar and Fed Rate Hike Expectations Weigh on Prices 
Asian Stocks Slip as Oil Rebounds Amid Fed Rate Hike Fears 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Bessent Says U.S. Must Strengthen Supply Chains and Economic Security 
Wall Street Ends Mixed as Tech Stocks Struggle Ahead of Micron Earnings 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Asian Stocks Slide as AI Rally Pauses, South Korean Chipmakers Lead Regional Decline 
Trump Requests $11 Billion More in Farm Aid as Rising Costs Pressure U.S. Farmers 
South Korea’s KOSPI Rebounds as Samsung and SK Hynix Lead Tech Stock Recovery 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Eli Lilly, an American pharmaceutical company, headquartered in Indianapolis, Indiana, issued a recall on a batch of its Glucagon Emergency Kits late last month. This is a type of therapy for diabetic patients experiencing an emergency situation.
According to Reuters, it turned out that the recalled emergency kit was manufactured at its factory plant in Indiana. The location is quite controversial because it was cited by the U.S. Food and Drug Administration this year for quality control issues, including substandard sanitation.
The health regulators inspected the said Eli Lilly plant and found violations related to quality control in the manufacturing of some of its products. Thus, with the recall, it was unavoidable for some to think that it may be connected to the unhygienic plant. Then again, there is no proof for this.
At any rate, Eli Lilly issued the voluntary recall on one batch of its Glucagon Emergency Kit on Sept. 25, and the FDA published the notice on Sept. 26. The health regulator indicated “loss of potency” as the reason for the recall. Moreover, Lilly was also said to have issued a recall in Canada as well.
The pharmaceutical firm recalled the said kits after receiving a report involving a patient who experienced seizures even after being injected with the drug. This is said to be a situation that indicates the treatment is not potent enough to provide relief or to work as it should. Based on the report, Eli Lilly said the failure could be due to the manufacturing process, but it did not specify or elaborate what exactly the main issue could be.
The drug is mainly used for the treatment of diabetes patients with dangerously low blood sugar. It was described as an anti-hypoglycemic agent and a gastrointestinal motility inhibitor for the treatment of severe hypoglycemia in patients with diabetes mellitus.
Meanwhile, in response to inquiries about the place of production for the recalled product, Eli Lilly confirmed to Reuters that the affected Glucagon Emergency Kit lots were indeed made at its Indianapolis facility. It added that the recalled drug had been distributed in Canada. Around 66,000 units were affected by the recall, and some 19,000 were distributed in the U.S. and Canada.
